Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Characterization of bone metastases from rapid autopsies of prostate cancer patients.

Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ.

Clin Cancer Res. 2011 Jun 15;17(12):3924-32. doi: 10.1158/1078-0432.CCR-10-3120. Epub 2011 May 9.

2.

Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.

Arnold RS, Fedewa SA, Goodman M, Osunkoya AO, Kissick HT, Morrissey C, True LD, Petros JA.

Bone. 2015 Sep;78:81-6. doi: 10.1016/j.bone.2015.04.046. Epub 2015 May 5.

3.

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL.

Hum Pathol. 2003 Jul;34(7):646-53.

PMID:
12874759
4.

Metastatic progression of breast cancer: insights from 50 years of autopsies.

Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, McCart Reed AE, Kutasovic JR, Morey AL, Marquart L, O'Rourke P, Lakhani SR.

J Pathol. 2014 Jan;232(1):23-31. doi: 10.1002/path.4288.

5.

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.

Chung LW, Baseman A, Assikis V, Zhau HE.

J Urol. 2005 Jan;173(1):10-20. Review.

PMID:
15592017
6.

Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.

Jernberg E, Thysell E, Bovinder Ylitalo E, Rudolfsson S, Crnalic S, Widmark A, Bergh A, Wikström P.

PLoS One. 2013 Nov 7;8(11):e77407. doi: 10.1371/journal.pone.0077407. eCollection 2013.

7.

Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.

Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH.

Cancer Res. 1996 Jul 1;56(13):3091-102.

8.

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW.

Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2).

PMID:
10881018
9.

A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.

Fradet A, Sorel H, Depalle B, Serre CM, Farlay D, Turtoi A, Bellahcene A, Follet H, Castronovo V, Clézardin P, Bonnelye E.

PLoS One. 2013 Sep 19;8(9):e75092. doi: 10.1371/journal.pone.0075092. eCollection 2013.

10.

Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.

Chakrabarti R, Robles LD, Gibson J, Muroski M.

Cancer Genet Cytogenet. 2002 Dec;139(2):115-25.

PMID:
12550771
11.

Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.

Heidenreich A, Pfister D, Porres D.

J Urol. 2015 Mar;193(3):832-8. doi: 10.1016/j.juro.2014.09.089. Epub 2014 Sep 22.

PMID:
25254935
12.

Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment.

Arnold RS, Sun CQ, Richards JC, Grigoriev G, Coleman IM, Nelson PS, Hsieh CL, Lee JK, Xu Z, Rogatko A, Osunkoya AO, Zayzafoon M, Chung L, Petros JA.

Prostate. 2009 Jan 1;69(1):1-11. doi: 10.1002/pros.20854.

13.

Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.

Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H.

Prostate. 2003 Mar 1;54(4):268-74.

PMID:
12539225
14.

Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.

Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schröder FH, van der Kwast TH, Bosman FT, van Dekken H.

Lab Invest. 1997 Nov;77(5):437-48.

PMID:
9389787
15.

Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.

Cancer Res. 2004 Dec 15;64(24):9209-16.

16.

Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.

Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R.

Clin Cancer Res. 2011 Aug 15;17(16):5287-98. doi: 10.1158/1078-0432.CCR-10-2619. Epub 2010 Dec 15.

17.

The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.

Fitzgerald KA, Guo J, Tierney EG, Curtin CM, Malhotra M, Darcy R, O'Brien FJ, O'Driscoll CM.

Biomaterials. 2015 Oct;66:53-66. doi: 10.1016/j.biomaterials.2015.07.019. Epub 2015 Jul 14.

PMID:
26196533
18.

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR.

PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17.

20.

Prostate stem cell antigen is overexpressed in prostate cancer metastases.

Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE.

Clin Cancer Res. 2005 Apr 1;11(7):2591-6.

Supplemental Content

Support Center